-
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q2 2024 Earnings Call Transcript
12 Aug 2024 12:23 GMT
… welcome to Cumberland Pharmaceuticals Second Quarter 2024 … Oncology, focuses on cancer clinics. So now, … drug like Caldolor can provide a cornerstone for many treatment … Sancuso, the first and only FDA approved prescription patch for the prevention of nausea …
-
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2024 Earnings Call Transcript
13 May 2024 13:36 GMT
… welcome to Cumberland Pharmaceuticals First Quarter 2024 … Medicaid coverage. And meanwhile, we also continue to feature Sancuso … effects associated with their chemotherapy cancer treatments. And additionally, … portfolio of FDA-approved medicines through 3 …
-
Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update
08 May 2024 02:32 GMT
… pharmaceutical company, today announced that its product portfolio of FDA … cancer patients by addressing certain side effects associated with their chemotherapy treatments … chemotherapy, the SANCUSO patch slowly and continuously releases the medicine …
-
Cumberland Pharmaceuticals Inc. (CPIX) Q1 2024 Earnings Call Transcript
12 May 2024 05:12 GMT
… welcome to Cumberland Pharmaceuticals First Quarter 2024 … Medicaid coverage. And meanwhile, we also continue to feature Sancuso … associated with their chemotherapy cancer treatments. And additionally, … several investigator-initiated trials. We do expect …
-
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results
05 Mar 2024 21:30 GMT
… cancer patients tolerate their chemotherapy treatments. Sancuso is the first and only FDA-approved prescription patch … trials for patients with a series of unmet medical … ;eubuwzon.
ABOUT CUMBERLAND PHARMACEUTICALS:
Cumberland Pharmaceuticals Inc. is the …
-
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q4 2023 Earnings Call Transcript
07 Mar 2024 17:11 GMT
… and welcome to Cumberland Pharmaceuticals 2023 Financial Report and … deliver our newest brand, Sancuso, to cancer patients. And our … in Antimicrobial Agents and Chemotherapy, detailing the results of … approved by the FDA for the treatment of hospital acquired …
-
Cumberland Pharmaceuticals to Announce Annual 2023 Financial Results
28 Feb 2024 09:14 GMT
… 47;eubuwzon.
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on … ;
Sancuso® (granisetron) transdermal system, for the prevention of nausea and … vomiting in patients receiving certain types of chemotherapy treatment; …
-
CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
24 May 2023 02:50 GMT
… Drug Administration (FDA) has cleared the Investigational New Drug … trial designed to enroll 128 patients in over 20 medical …
Sancuso® (granisetron) transdermal, for the prevention of nausea … -pharmaceuticals-announces-fda-clearance-of-ind-for-new-treatment- …
-
United States Transdermal Patch Market Report 2023: Dosage, Price & Clinical Trials Insights to 2029 - Focus on Opioid, Cardiovascular Diseases, Neurological Disorders, and Hormonal Therapy - ResearchAndMarkets.com
23 Nov 2023 17:44 GMT
… transdermal patches is expected to experience significant growth. Pharmaceutical companies … health diseases such as cancer or its treatment, as well as … Transdermal Patch
10.3 Granisetron Transdermal Patch (Sancuso)
11. US Transdermal Patch Clinical Trials …
-
Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results
08 Nov 2023 00:37 GMT
… pharmaceutical company, announced today that its product portfolio of FDA … FIGHT DMD™ trial, a … nausea and vomiting in patients receiving certain types of chemotherapy treatment … chemotherapy, the Sancuso patch slowly and continuously releases the medicine …